Compare FHN & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHN | BIO |
|---|---|---|
| Founded | 1864 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7700 |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 8.2B |
| IPO Year | N/A | N/A |
| Metric | FHN | BIO |
|---|---|---|
| Price | $24.51 | $303.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 4 |
| Target Price | $24.61 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 5.5M | 155.9K |
| Earning Date | 01-15-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | ★ 20.88 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $3,184,000,000.00 | $2,557,500,000.00 |
| Revenue This Year | $10.95 | $1.62 |
| Revenue Next Year | $2.82 | $2.26 |
| P/E Ratio | $14.81 | ★ N/A |
| Revenue Growth | ★ 3.68 | N/A |
| 52 Week Low | $15.19 | $211.43 |
| 52 Week High | $24.75 | $373.69 |
| Indicator | FHN | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 72.00 | 44.66 |
| Support Level | $23.54 | $298.78 |
| Resistance Level | $24.75 | $307.07 |
| Average True Range (ATR) | 0.42 | 7.77 |
| MACD | 0.07 | -0.88 |
| Stochastic Oscillator | 87.89 | 35.90 |
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.